SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
Buchanan, S.G., Hendle, J., Lee, P.S., Smith, C.R., Bounaud, P.Y., Jessen, K.A., Tang, C.M., Huser, N.H., Felce, J.D., Froning, K.J., Peterman, M.C., Aubol, B.E., Gessert, S.F., Sauder, J.M., Schwinn, K.D., Russell, M., Rooney, I.A., Adams, J., Leon, B.C., Do, T.H., Blaney, J.M., Sprengeler, P.A., Thompson, D.A., Smyth, L., Pelletier, L.A., Atwell, S., Holme, K., Wasserman, S.R., Emtage, S., Burley, S.K., Reich, S.H.(2009) Mol Cancer Ther 8: 3181-3190
- PubMed: 19934279 
- DOI: https://doi.org/10.1158/1535-7163.MCT-09-0477
- Primary Citation of Related Structures:  
3DKC, 3DKF, 3DKG - PubMed Abstract: 
The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics. Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers. In other cancers, such as glioblastoma, autocrine activation of MET has been demonstrated ...